Dermatology

For kids experiencing moderate to severe urticaria that improve with single-dose antihistamine, do you scale up the manufacturer packaging dosages up ...

1 Answer available

What treatment regimen do you start for patients who present with mucous membrane pemphigoid?

Have you prescribed Rituximab and IVIG simultaneously for patients?

1 Answer available

How do you manage patients with erosive pustular dermatosis?

1 Answer available

With the increasing reports of correlation of frontal fibrosing alopecia and titanium dioxide sunscreens, do you advise patients against the use of micronized sunscreens on the face?

1 Answer available

How do you approach the management of patients with neuropathic itch?

Do you use any compounded topical therapies?

1 Answer available

What are your preferred treatment options for patients with chronic non-healing leg ulcers?

1 Answer available

How do you manage patients with recurrent periorificial dermatitis?

1 Answer available

How do you differentiate erythrodermic mycosis fungoides and Sezary syndrome - is it primarily based on the burden of blood involvement of malignant cells?

Mycosis fungoides and Sezary syndrome are thought to be distinct genotypically and phenotypically. It is my understanding that Sezary syndrome typical...

2 Answers available

What therapies do you recommend for preventing keloid recurrence after surgical resection?

1 Answer available

How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?

2 Answers available

How do you manage patients with Dercum's disease?

2 Answers available

How do you manage anti-Mi-2 positive dermatomyositis with predominantly cutaneous manifestations?

1 Answer available

What IHC stains do you routinely use for identifying invasive squamous cell carcinomas?

1 Answer available

How do you approach treating patients with trigeminal trophic syndrome?

2 Answers available

How do you approach preventing and treating bruising after filler injections?

1 Answer available

How often do you order imaging to assess for possible degenerative joint disease in the spine in patients with neuropathic itch?

2 Answers available

How do you manage patients with alopecia totalis who are not candidates for JAK inhibitors?

1 Answer available

What is your approach to treating patients with dupilumab induced facial redness?

2 Answers available

Do you recommend the HPV vaccine for patients with recalcitrant verruca vulgaris?

2 Answers available

How do you manage patients with chronic flushing that do not respond to beta-blockers?

1 Answer available

How do you manage patients with bullous pemphigoid who have IgE autoantibodies to BP180?

1 Answer available

How do you manage patients with rapidly progressing vitiligo?

1 Answer available

How do you manage patients with cicatricial pemphigoid refractory to doxycycline and dapsone?

1 Answer available

How do you manage patients with chemotherapy-induced paronychia?

1 Answer available

How do you approach treating cutaneous PAN?

Other than inflammatory markers and following symptoms/exam, do you need any other specific monitoring for progression to systemic disease?

1 Answer available

How would you manage a patient with essential thrombocythemia and persistent pruritus despite adequate control of CBC with hydroxyurea and aspirin?

ET is JAK2+

1 Answer available

How do you manage psoriasis in pregnant patients?

3 Answers available

How do you approach restarting biologics for psoriasis patients who have discontinued therapy for 3-6 months?

Do you prefer restarting the biologic with the loading or maintenance dosing?

1 Answer available

What are your preferred treatment options for patients with cholestatic pruritus who do not respond to light therapy?

2 Answers available

Would you offer palliative radiation for painful bone metastases in a patient with scleroderma?

1 Answer available

How would you treat localized cutaneous PAN recalcitrant to high-dose steroids?

1 Answer available

How do you approach treating patients with erythema nodosum recalcitrant to NSAIDs?

1 Answer available

Do you recommend a deep shave biopsy or punch biopsy for sampling concerning melanocytic lesions?

3 Answers available

Does calcinosis appear differently in patients with dermatomyositis compared to systemic sclerosis?

1 Answer available

How do you approach patients with onychomycosis that does not respond to terbinafine and prolonged courses of fluconazole?

Would you switch to itraconazole or perform fungal cultures?

2 Answers available

How do you differentiate atopic dermatitis from mycosis fungoides histologically?

1 Answer available

How do you manage patients with suspected chronic contact dermatitis and negative patch testing?

1 Answer available

How long do you give systemic therapies or skin directed therapies to work before changing treatments in patients with diffuse skin limited mycoses fungoides?

Do you have a preferred sequence of therapies for diffuse skin limited MF?

1 Answer available

Would you take any precautions of plan radiation therapy differently for a patient with head and neck cancer who has active Bullous Pemphigoid in the mucosal area that will be radiated?

1 Answer available

Do you divide interpolation flaps 2 or 3 weeks after the initial surgery?

Are there specific cases where you would or would not consider early flap division?

1 Answer available

Would you still consider durvalumab consolidation after definitive chemoradiation for patients with Stage III NSCLC who are on stable weekly methotrexate dosing for psoriasis/psoriatic arthritis?

1 Answer available

Is there an age cut off below you would not treat a keloid with radiation post surgical excision?

Assuming it has previously been treated with excision and steroid injections? Is it reasonable to treat a bothersome keloid in a pediatric patient aft...

6 Answers available

How do you utilize methotrexate and/or hydroxychloroquine in the setting of limited scleroderma/CREST?

1 Answer available

Have you found success in managing refractory hidradenitis suppurativa with ertapenem?

1 Answer available

How do you counsel patients on preventing and treating "maskne"?

2 Answers available

Does irradiation of a patient with pyoderma gangrenosum carry risk of morbidity similar to necrosis caused by minor surgery?

1 Answer available

What is your approach to severe discoid lupus refractory to conventional topical and systemic therapies?

(Refractory to mycophenolate, azathioprine, and methotrexate. UpToDate suggests thalidomide or IVIG with mixed efficacy, while there are some case rep...

4 Answers available

What is your preferred infliximab dosing strategy for hidradenitis suppurativa?

2 Answers available

How would you approach treatment of an elderly patient with recurrent atypical fibroxanthoma (malignant spindle cell neoplasm) after Mohs surgery?

What is the role for surgery vs RT?

1 Answer available

How would you manage eccrine porocarcinoma of the great toe with positive superficial groin and pelvic lymph nodes s/p toe amputation and pelvic lymph node dissection?

Would you offer systemic therapy and/or radiation therapy to groin/pelvis?

1 Answer available

When tapering moderate to high doses of long term steroids do you routinely monitor for adrenal insufficiency?

Do you attempt to taper fully or maintain at a low dose?

2 Answers available

Would the diagnosis of skin-only morphea (localized scleroderma) alter treatment recommendations for localized anal cancer?

1 Answer available

How do you manage eyebrow and eyelash involvement in patients with alopecia areata?

1 Answer available

How do you think about biologic use in patients with underlying HIV infection?

2 Answers available

How do you manage patients with chronic telogen effluvium?

1 Answer available

What is your approach to treating dermatomyositis patients with pruritus recalcitrant to oral and topical steroids?

2 Answers available

How do you approach treating patients with acne keloidalis nuchae who do not respond to a potent topical steroid or retinoid?

1 Answer available

How do you manage eruptive squamous atypia that does not respond to intralesional 5-fluorouracil or intralesional methotrexate?

1 Answer available

Is a biopsy of either skin or muscle always indicated in the diagnosis of dermatomyositis?

1 Answer available

How do you approach screening for additional malignancies in patients with a history of CTCL?

0 Answers available

What is your approach to treating patients with chronically brittle nails?

1 Answer available

What is your approach to starting and monitoring methotrexate in elderly patients?

1 Answer available

What is your approach to treating patients with lichen planopilaris who do not respond to hydroxychloroquine?

0 Answers available

What is your approach to managing patients with CCCA who do not respond to ILK or doxycycline?

1 Answer available

How do you manage patients with yellow nail syndrome?

What are your preferred treatment methods other than topical Vitamin E and azole antifungals?

1 Answer available

How do you manage patients with twenty nail dystrophy of unclear etiology?

1 Answer available

What are some of your preferred treatment options for managing facial papules that occur in the setting of lichen planopilaris?

1 Answer available

What therapies do you use in patients with cutaneous lupus recalcitrant to topical steroids?

1 Answer available

What is your approach to treating patients with melasma that does not respond to hydroquinone-based topical therapies?

2 Answers available

How do you approach treating patients with delusions of parasitosis who can not tolerate an antipsychotic?

1 Answer available

How do you approach the use of commercial testing such as AVISE CTD in clinical practice?

1 Answer available

Do you measure drug levels (particularly hydroxychloroquine or mycophenolate) in your lupus patients?

Several speakers at ACR 2021 commented on the important role of drug levels in the management of these patients and cautioned against adding medicatio...

1 Answer available

Is whole body phototherapy for skin disorders a contraindication to chest wall or breast radiation?

If so, how long after phototherapy (eg. NB-UVB) is it safe to proceed with RT? See: Systemic review of phototherapy for pruritic skin disorders

1 Answer available

How do you clinically distinguish between cutaneous lupus with photosensitivity and polymorphic light eruption-like reactions?

1 Answer available

What is the role for angiography in the workup of digital ischemia?

Do you obtain vascular imaging routinely in these cases, and if so, do you use cross-sectional or invasive angiography?

1 Answer available

How would you manage a nodal recurrence of cutaneous SCC if the patient is unable to receive surgery for 6-8 weeks?

In a patient who would be otherwise fit for surgery +/- adjuvant RT, and the delay is caused by COVID-related OR staffing issues, what would be your a...

1 Answer available

What is your approach for disease activity monitoring in patients with sarcoidosis?

1 Answer available

Is it ever reasonable to switch to a different TNFi as opposed to switching to an agent in a different class in a case of TNFi induced lupus or psoriasis?

In other words, do we think of TNFi induced lupus and TNFi induced psoriasis as a drug effect or a class effect?

1 Answer available

How do you approach breast conserving therapy in a woman who has formed bothersome keloids after prior surgeries?

Is there any alteration in approach from the medical, surgical, or radiation oncology perspective that can mitigate the risk of forming keloids withou...

3 Answers available

When would you offer post-op radiation for the treatment of sebaceous carcinoma of the eyelid?

2 Answers available

What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?

1 Answer available

How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?

Would you change rituximab maintenance dose or schedule?

1 Answer available

How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?

1 Answer available

What is your methotrexate initiation strategy in DMARD-naive RA patients?

Specifically: starting dose, rapidity of up-titration, frequency of lab monitoring, frequency of office visits, and timing of assessment for treatment...

2 Answers available

What therapies have you had the most success with for calcinosis cutis in dermatomyositis patients?

1 Answer available

How would you approach an early inguinal recurrence after surgical resection of Merkel Cell carcinoma in the popliteal region?

2 Answers available

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

ADVOCATE trial

1 Answer available

How would you manage a patient with cutaneous SCC of the lower extremity with isolated inguinal nodal involvement?

What is the role and sequence of surgery and/or RT? Which nodal levels would you include in your RT field(s)?

1 Answer available

When is it necessary to monitor the QTc interval in patients on hydroxychloroquine?

2 Answers available

What would be your next step in management of a dermatomyositis patient on hydroxychloroquine and methotrexate whose skin is still active?

Muscle disease is quiescent and no other manifestations such as ILD

1 Answer available

How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?

In the ADVOCATE trial, patients were not re-dosed with rituximab.

1 Answer available

Are there particular subsets of AAV patients in which avacopan is more effective?

E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...

1 Answer available

Is it okay to use medications associated with drug-induced lupus in patients with SLE?

1 Answer available

How would you approach refractory gangrenous Raynaud's secondary to type one cryoglobulins?

What if the patient has MGUS? Do patients with type 1 cryoglobulins need a bone marrow biopsy as part of the work up?

1 Answer available

Is there a role for adjuvant systemic therapy (in addition to adjuvant radiation) in an early-stage, resected cutaneous angiosarcoma of the head/neck?

Post-auricular cutaneous angiosarcoma, pT1 (19 mm) with negative margins. Unclear if there is any indication for systemic therapy, given early stage a...

1 Answer available

How would you treat a patient with an keratoacanthoma of the right nasal ala?

What approaches (surgical vs non-surgical) offer the best cosmesis for keratoacanthoma (low grade squamous cell carcinoma) ?

1 Answer available

What type of surveillance would you recommend following resection of primary mucinous carcinoma of the skin?

1 Answer available

Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?

1 Answer available

How would you approach treatment of a patient with asymptomatic, oligometastatic basal cell carcinoma?

Is there a role for radiation? Does your approach differ depending on site(s) of disease, and/or if the patient has Basal-Cell Nevus (Gorlin) sy...

1 Answer available

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?

1 Answer available

What treatment options are available for patients with spondyloarthritis who develop biologic-induced psoriasis?

1 Answer available

Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?

1 Answer available

Is there a role for measuring hydroxychloroquine blood levels in clinical practice?

If so, are there specific patient populations for which you would use this metric?

1 Answer available

Would you offer definitive radiation therapy for a Merkel cell carcinoma in which surgical resection would be disfiguring or result in significant dysfunction?

In general, how would you approach such a case with regards to creation of your treatment volumes and dose-fractionation?

1 Answer available

Would you continue cemiplimab or pembrolizumab following resection of initially unresectable cutaneous squamous cell carcinoma?

What if pathology showed NED?

3 Answers available

What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide?

1 Answer available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

What is your preferred radiotherapy regimen for palliative treatment of cutaneous T cell lymphoma?

1 Answer available

Should venous thrombosis in a patient with Behcet syndrome be treated with both immunosuppression and anticoagulation?

1 Answer available

How do you screen for colon cancer in patients with Behcet syndrome with colonic involvement?

1 Answer available

What is the biologic of choice in a patient with RA and history of non-melanoma skin cancer?

2 Answers available

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

2 Answers available

How would you manage a small recurrent melanoma of the lower eyelid in a patient deemed inoperable?

Would you recommend radiation therapy or immunotherapy? If proceeding with radiation therapy, what dose-fractionation and technique would you utilize?

2 Answers available

Would you recommend post-op RT for an ulcerated Clark's level IV melanoma of the zygomatic/preauricular region following a WLE with diffuse melanoma in-situ at the margins?

What dose-fractionation schedule would you utilize?

1 Answer available

Which immunosuppressed patients with SLE would benefit from antibiotic prophylaxis to prevent pneumocystis pneumonia?

1 Answer available

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

2 Answers available

Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?

2 Answers available

Is it ever appropriate to use hydroxychloroquine temporarily in higher doses (more than 5mg/kg) to control lupus activity such as skin manifestations?

1 Answer available

How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?

1 Answer available

What agents can you use for treatment induction besides rituximab in cryoglobulinemic vasculitis (without hepatitis)?

1 Answer available

Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?

2 Answers available

Is there benefit in switching between sonedegib to vismodegib or vice versa for patients with unresectable basal cell carcinoma of the face that progresses on first line hedgehog inhibitor?

1 Answer available

What is your first treatment of choice in patients with dermatomyositis sine myositis?

1 Answer available

How do you assess transaminitis in a patient with sarcoidosis with known liver involvement being treated with methotrexate?

1 Answer available

What is your approach to elective radiation of the neck with primary cutaneous squamous cell carcinoma?

When do you electively treat the ipsilateral versus ipsi- and contralateral neck?

1 Answer available

How do you screen dermatomyositis patients for malignancy if they have a high risk antibody profile (NXP-2/TIF1gamma positive) and their initial screen is negative?

1 Answer available

Do you continue hydroxychloroquine in lupus patients who develop cardiomyopathy?

1 Answer available

When is a biopsy necessary to diagnose relapsing polychondritis?

1 Answer available

What is your approach to bladder cancer surveillance in patients who have received cyclophosphamide?

1 Answer available

How do you manage calcium and vitamin D supplementation in patients with sarcoidosis on chronic steroids?

1 Answer available

What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?

1 Answer available

How would you approach the treatment of a low grade adnexal carcinoma of the scalp in a patient with prior history of WBRT as a child?

This particular case involves a patient with a frontal scalp low grade eccrine carcinoma status-post excision with positive margin complicated by...

1 Answer available

Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?

If you use both, how do you decide which to use for a particular patient?

2 Answers available

Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?

1 Answer available

Are there any clinical situations in which checking for anti-chromatin antibodies is helpful?

1 Answer available

How do you counsel patients who ask if there are any dietary modifications they can make to help control their autoimmune disease?

1 Answer available

Is there a minimum work-up necessary in patients with an ANA greater than 1:160 and no clinical symptoms suggestive of lupus (i.e., specific antibodies, UA)?

2 Answers available

Do you use hydroxychloroquine for prevention of neonatal lupus in patients with a positive SSA who are planning on becoming pregnant?

1 Answer available

How would you approach a patient with metastatic Merkel cell carcinoma to the axillary/supraclavicular lymph nodes of unknown primary?

Would you recommend locoregional radiation therapy or systemic or immunotherapy alone? If you would consider radiation therapy, what would be your rec...

2 Answers available

How would you approach the post-operative radiation treatment volumes for a Merkel cell carcinoma of the hand?

Would you treat the primary site alone, include the hand and arm lymphatics to the epitrochlear nodes (one continious treatment volume from hand to el...

1 Answer available

Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?

1 Answer available

What is your preferred setup/immobilization for patients with cutaneous malignancy of the toe involving the medial aspect of the digit?

1 Answer available

Would you offer adjuvant RT for a small merkel cell carcinoma of the lateral canthus with a close margin?

Given the location but no other high risk features would you offer RT? If so, what dose and fields?

2 Answers available

Would you recommend adjuvant radiation for an atypical fibroxanthoma of the scalp that is completed resected with +PNI and +LVI?

What pathologic features are most important when evaluating the possible need for adjuvant therapy?

1 Answer available

How would you manage a high risk SCC of the scalp that has wound healing issues after Mohs surgery?

Would you offer RT? If so, shat dose fractionation do you recommend?

2 Answers available

Would you offer adjuvant radiation to the surgical bed for a Merkel cell carcinoma of the upper extremity with low-risk features as per the NCCN Guidelines?

*Negative margins, <1cm in size, no LVI, negative SLNB, not immunocompromised, no prior surgery (as well as a negative PET/CT scan).

2 Answers available

How do your adjuvant treatment recommendations change, if at all, for clinically node positive Stage III desmoplastic melanoma?

1 Answer available

Are there guidlines for elective coverage of nodal basins in head and neck for skin cancer removed in the area?

4 Answers available

Is there a role for treating actinic keratosis with superficial radiation therapy to widespread areas on scalp?

If so, what is your suggested dose/fractionation?

1 Answer available

Would you recommend surgery +/- adjuvant XRT or definitive XRT in elderly patients with recurrent squamous cell carcinoma of the ear with direct invasion through the cartilage of the helix?

1 Answer available

What are the indications for adjuvant radiotherapy for basal cell carcinoma of the skin of the head and neck?

NCCN lists only substantial perineural invasion. What about other high-risk adverse features such as histologic subtype, multiple recurrences, d...

1 Answer available

What risk factors prompt you to treat an early-stage nasal squamous cell carcinoma of the skin with post-operative radiation to the primary and/or elective nodal radiation?

When elective nodal radiation is recommended, which nodes would you treat (i.e. facial, pre-auricular, peri-parotid, levels I-III, etc.)?

1 Answer available

Would you offer adjuvant radiation for a <1 cm preauricular sebaceous carcinoma after wide local excision?

Patient underwent a shave biopsy of a 6x5x2mm preauricular lesion that showed moderatley differentiated sebaceous carcinoma with deep and lateral marg...

1 Answer available

How would you manage treatment of keloid that is so large it requests a graft?

What dose/fractionation would yield the lowest risk of graft failure? Does your treatment management change based of location, ex the ear vs back?

1 Answer available

When would you recommend adjuvant radiation therapy for a patient with a completely resected (negative margins) dermatofibrosarcoma protuberans?

1 Answer available

Do you offer radiation in the setting of a resected desmoplastic melanoma with negative margins given that several retrospective studies show a local control benefit?

If so, how large of a margin would you place on the primary lesion and would you incorporate any adjacent lymph node levels?

3 Answers available

When does perineural invasion for a squamous cell carcinoma of the skin of the head and neck merit adjuvant radiotherapy?

Following Mohs surgery and in the absence of other high risk features, do you offer RT for any PNI? A single nerve < 0.1 mm? A single ne...

3 Answers available

What is the best management for recurrent basal cell carcinoma after prior radiation and vismodegib?

Would re-irradiation be an appropriate option? What dose/field would you incorporate? If treating with standard fractionation, would you take the enti...

1 Answer available

For a patient treated with Mohs surgery for a high risk skin cancer of the head/neck, do you post-operatively treat all scars (including those created due to subsequent closure) to full dose?

I have seen some patients who may undergo large complex closures (sometimes as a separate procedure) for smaller lesions with resulting scars that sig...

3 Answers available

Do you treat fully resected squamous cell carcinoma of the ear with cartilage invasion with adjuvant radiation?

If so, what is your treatment volume?

1 Answer available

What is the value of resection in high risk (but small or early stage) skin cancers at the medial canthus?

Is modern surgical/reconstruction treatment superior to radiation therapy? If contact brachytherapy or superficial (orthovoltage) therapy isnt possib...

1 Answer available

Papers discussed in this category

Br J Radiol,

The risks of treating keloids with radiotherapy.

Burns, 2014 Apr 24

Up-to-date approach to manage keloids and hypertrophic scars: a useful guide.

Pediatrics, 2013-01

Nine-month-old patient with bilateral earlobe keloids.

Pediatrics, 2016-02

Scar Management in the Pediatric and Adolescent Populations.

International journal of radiation oncology, biology, physics, 2018-09-01

Dose Effect in Adjuvant Radiation Therapy for the Treatment of Resected Keloids.

Cancer, 1995 May 1

Reirradiation of recurrent skin cancer of the face. A successful salvage modality.

Ann Surg Oncol, 2003 May

Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma.

American journal of surgery, 2001-12

The clinical behavior of desmoplastic melanoma.

World J Surg, 1992 Mar-Apr

Desmoplastic melanoma: patterns of recurrence.

Cancer, 2005-10-01

Wide excision without radiation for desmoplastic melanoma.

Journal of contemporary brachytherapy, 2017-04

Electronic brachytherapy management of atypical fibroxanthoma: report of 8 lesions.

Melanoma research, 2015-04

The emerging role of radiotherapy for desmoplastic melanoma and implications for future research.

Nature, 2018-01-18

High response rate to PD-1 blockade in desmoplastic melanomas.

Cureus, 2019 Jun 18

Desmoplastic Melanoma: Clinical Characteristics and Survival in the US Population.

PloS one, 2015

Clinicopathologic predictors of survival in patients with desmoplastic melanoma.

The British journal of dermatology, 2019-02

Local recurrence and quality of life after adjuvant radiation therapy in high-risk squamous cell carcinoma.

JAAD Case Rep, 2019 Jun 26

Radiation therapy for primary cutaneous γδ T-cell lymphoma: Case report and literature review.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Medicine (Baltimore),

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers.

, 2016 Aug 30

Treatment of clinically amyopathic dermatomyositis in adults: a systematic review.

J. Am. Coll. Cardiol.,

Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.

Arthritis and rheumatism, 1982-11

The 1982 revised criteria for the classification of systemic lupus erythematosus.

Arthritis and rheumatism, 2012-08

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

, 2019 Aug 06

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Arthritis Rheum.,

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Ann. Rheum. Dis., 2018 Apr 25

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Ann. Rheum. Dis., 2017 May 25

Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Ann. Rheum. Dis., 2018 May 03

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

Medicine, 1976-05

Relapsing polychondritis: prospective study of 23 patients and a review of the literature.

Arthritis and rheumatism, 2010-01

Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.

J. Rheumatol., 2019 Sep 01

Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study.

Pract Radiat Oncol, 2019 Dec 09

Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline.

Annals of the rheumatic diseases, 2009-03

EULAR recommendations for the management of primary small and medium vessel vasculitis.

JAMA ophthalmology, 2014-12

The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.

Can J Ophthalmol,

Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.

J Am Acad Dermatol, 2016 Feb 03

The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.

JAMA network open, 2018-11-02

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008-10

Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.

Clin Rheumatol, 2006 Dec 21

Rheumatol Int, 2020 Sep 18

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.

Arthritis Rheumatol, 2016 Jan

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Kidney international reports, 2018-03

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

N Engl J Med, 2020 Feb 13

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Rheumatology (Oxford),

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Journal of psoriasis and psoriatic arthritis, 2019-04

TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.

Front Pharmacol, 2019 Mar 26

Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.

Nat Rev Dis Primers, 2018 Aug 02

Cryoglobulinaemia.

N Engl J Med, 2021 Feb 18

Avacopan for the Treatment of ANCA-Associated Vasculitis.

Int J Clin Pract, 2021 Mar 24

Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.

Mod Rheumatol, 2021 Feb 09

QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.

Heart Rhythm, 2020 Jun 28

Effects of hydroxychloroquine treatment on QT interval.

Arthritis care & research, 2018-03

Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.

J Clin Rheumatol, 2020 Sep 18

Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase.

Cureus, 2020 Aug 02

A Study on the Relevance of Glucose-6-Phosphate Dehydrogenase Level Screening in Patients with Rheumatic Diseases Prior to Initiating Treatment With Hydroxychloroquine.

Ann Intern Med,

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

Ann Rheum Dis, 2011 Nov 29

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

Lancet Oncol, 2019 Dec

Sebaceous carcinoma: evidence-based clinical practice guidelines.

Respir Med, 2012 Apr 09

The treatment of pulmonary sarcoidosis.

Am J Respir Crit Care Med,

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Seminars in arthritis and rheumatism, 2010-12

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Clin Exp Rheumatol, 2012 Oct 17

Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?

Inflamm Bowel Dis,

Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.

Am J Clin Dermatol,

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2001

Polyarteritis nodosa: spectrum of angiographic findings.

International journal of clinical rheumatology, 2010

Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.

Lupus science & medicine, 2014

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.

The Journal of rheumatology, 2015-11

Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.

Ophthalmology, 2016-06

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).

Lupus science & medicine, 2017

Cell-bound complement activation products in SLE.

Journal of immunology research, 2017

Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus.

Lupus science & medicine, 2018

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Arthritis care & research, 2019-07

Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study.

Clin Pharmacol Ther, 2018 Jun

A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

Lupus Sci Med, 2016

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.

Rev Med Interne, 2016 Oct 13

[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].

JAMA Dermatol,

Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.

Lupus Sci Med, 2016 Feb 01

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

Lupus Sci Med,

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.

ACR Open Rheumatol, 2020 Oct 12

Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).

Arthritis Rheumatol, 2021 May 02

Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.

Ann Rheum Dis, 2012 Nov 10

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).

Arthritis Rheum,

Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.

Lupus,

Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.

Arthritis Rheumatol, 2020 Jan 07

Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.

Lupus Sci Med, 2019

Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery.

Journal of medical case reports, 2010-05-22

Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report.

Ann Med Surg (Lond), 2017 Jun 20

Porocarcinoma; presentation and management, a meta-analysis of 453 cases.

Case Rep Oncol, 2021 May 10

Eccrine Porocarcinoma: A Challenging Diagnostic and Therapeutic Tumoral Entity.

J Clin Oncol,

Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials.

Acta Gastroenterol Belg,

Cholestatic pruritus : an update.

Int J Dermatol,

Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease.

J Am Acad Dermatol,

Oral dexamethasone pulse treatment for vitiligo.

Br J Dermatol, 2018 Oct 10

Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo.

Dermatologic therapy, 2018-11

Tofacitinib for the treatment of lichen planopilaris: A case series.

Dermatol Ther (Heidelb), 2019 Nov 20

Pathogenesis, Clinical Signs and Treatment Recommendations in Brittle Nails: A Review.

J Am Acad Dermatol, 2019 Mar 11

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

J Am Acad Dermatol, 2019 May 13

Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa.

Dermatology,

Infliximab for the treatment of hidradenitis suppurativa.

Best practice & research. Clinical rheumatology, 2013-06

Cutaneous lupus erythematosus: diagnosis and treatment.

Dermatol Ther, 2016 Apr 12

Review of treatment for discoid lupus erythematosus.

The Lancet. Respiratory medicine, 2016-09

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Journal of the American College of Surgeons, 2011-04

Shave biopsy is a safe and accurate method for the initial evaluation of melanoma.

Am J Surg,

Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma.

J Immunother Cancer,

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.

Journal of the American Academy of Dermatology, 2011-07

Accelerated takedown of the paramedian forehead flap at 1 week: indications, technique, and improving patient quality of life.

JAMA Dermatol,

Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

J Dermatol,

Cutaneous polyarteritis nodosa: a clinical and histopathological study of 20 cases.

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Minerva Gastroenterol Dietol, 2016 Sep 07

Glutathione in the treatment of liver diseases: insights from clinical practice.

Free Radic Biol Med,

Effect of liver cirrhosis and age on the glutathione concentration in the plasma, erythrocytes, and gastric mucosa of man.

Ann Plast Surg,

Optimizing Radiotherapy for Keloids: A Meta-Analysis Systematic Review Comparing Recurrence Rates Between Different Radiation Modalities.

Journal of psychiatric practice, 2018-11

Association Between Delusions of Infestation and Prescribed Narcotic and Stimulant Use.

Journal of the American Academy of Dermatology, 2019-05

Diagnosis and management of delusional parasitosis.

Med Hypotheses, 2006 Nov 28

Delusional parasitosis and the dopamine transporter. A new insight of etiology?

J Am Acad Dermatol, 2021 Apr 18

Stimulant use in patients presenting with psychocutaneous disorders.

Prog Neuropsychopharmacol Biol Psychiatry,

Effects of pimozide on the psychopathology of delusional disorder.

Antimicrob Agents Chemother, 2008 Nov 17

A small-molecule screen identifies the antipsychotic drug pimozide as an inhibitor of Listeria monocytogenes infection.

Journal of investigational allergology & clinical immunology, 2007

Use of antihistamines in pediatrics.

Int Arch Allergy Immunol, 2018 Sep 25

Antihistamines: Recommended Dosage - Divergence between Clinical Practice and Guideline Recommendations.

Eur J Dermatol,

Response of recalcitrant generalized morphea to intravenous immunoglobulins (IVIg): three cases and a review of the literature.

Rheum Dis Clin North Am, 2020 Aug

Risk Factors and Cancer Screening in Myositis.

Rheumatology (Oxford),

A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.

Dermatol Clin,

Skin Cancer Risk (Nonmelanoma Skin Cancers/Melanoma) in Vitiligo Patients.

J Am Acad Dermatol, 2014 Sep 19

Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo.

Br J Dermatol,

Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners.

East Afr Med J,

PRIMARY MALIGNANT AMELANOTIC MELANOMA ARISING FROM A VITILIGO PATCH OF AN AFRICAN TANZANIAN: CASE REPORT.

Int J Dermatol,

Molecular analysis of vitiligo lesions reveals sporadic melanocyte survival.

J Pathol,

Melanocytes are not absent in lesional skin of long duration vitiligo.

Sci Rep, 2021 Oct 12

Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan.

Acta Derm Venereol,

Prediction of the Occurrence of Melanoma and Non-melanoma Skin Cancer in Patients with Vitiligo.

Br J Dermatol, 2019 Sep 18

The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea.

Br J Dermatol, 2019 Oct 16

Vitiligo and skin cancer: is it a question of ethnicity?

The British journal of dermatology, 2019-11

Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice.

Frontiers in immunology, 2019

Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies.

J Am Acad Dermatol, 2020 Sep 04

Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective.

Rheumatology (Oxford),

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.

Case reports in rheumatology, 2017

A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature.

Contact Dermatitis,

Contact allergy to dental restorative materials in patients with oral lichenoid lesions.

Oral Surg Oral Med Oral Pathol Oral Radiol, 2012 Mar 26

Clinical and histologic healing of lichenoid oral lesions following amalgam removal: a prospective study.

J Am Dent Assoc,

The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review.

Oral Oncol, 2006 Nov 16

The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients.

Am J Clin Dermatol,

Acquired palmoplantar keratoderma.

The American Journal of dermatopathology, 2013-07

SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics.

The American journal of surgical pathology, 2018-03

Distinguishing Neurofibroma From Desmoplastic Melanoma: The Value of p53.

The American journal of surgical pathology, 2018-11

PRAME Expression in Melanocytic Tumors.

Appl Immunohistochem Mol Morphol,

SOX10 expression in malignant melanoma, carcinoma, and normal tissues.

Pathology, 2016 Aug 28

SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens.

Am J Dermatopathol,

Sox10-Positive Cells Within Scars: A Potential Diagnostic Pitfall.

Am J Dermatopathol,

SOX-10 and S100 Negative Desmoplastic Melanoma: Apropos a Diagnostically Challenging Case.

J Am Acad Dermatol, 2022 Jun 23

Value of Permanent Pathology for Debulk and Mohs Specimens during Mohs Micrographic Surgery for Cutaneous Squamous Cell Carcinoma: A Retrospective Cohort Study.

Dermatol Surg,

Utility of Debulk Specimens During Mohs Micrographic Surgery for Cutaneous Squamous Cell Carcinoma.

Arch Dermatol,

Sebaceous gland inhibition from combined glucocorticoid-estrogen treatment.

Dermatology

Questions discussed in this category

Papers discussed in this category

Related Topics